314 related articles for article (PubMed ID: 29208204)
21. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
Vo AA; Aubert O; Haas M; Huang E; Zhang X; Choi J; Peng A; Najjar R; Sethi S; Ammerman N; Lim K; Jordan SC
Transplantation; 2019 Dec; 103(12):2666-2674. PubMed ID: 30883456
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step.
Lachmann N; Duerr M; Schönemann C; Pruß A; Budde K; Waiser J
J Immunol Res; 2017; 2017():6872046. PubMed ID: 28255562
[TBL] [Abstract][Full Text] [Related]
23. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
Wan SS; Ying TD; Wyburn K; Roberts DM; Wyld M; Chadban SJ
Transplantation; 2018 Apr; 102(4):557-568. PubMed ID: 29315141
[TBL] [Abstract][Full Text] [Related]
24. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
[TBL] [Abstract][Full Text] [Related]
25. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib for the treatment of chronic antibody-mediated kidney allograft rejection: a case report.
Schwaiger E; Regele H; Wahrmann M; Werzowa J; Haidbauer B; Schmidt A; Böhmig GA
Clin Transpl; 2010; ():391-6. PubMed ID: 21696056
[TBL] [Abstract][Full Text] [Related]
27. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
28. Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation.
Naciri Bennani H; Daligault M; Noble J; Bardy B; Motte L; Giovannini D; Emprou C; Fiard G; Imerzoukene F; Bourdin A; Masson D; Janbon B; Malvezzi P; Rostaing L; Jouve T
J Clin Apher; 2021 Aug; 36(4):584-594. PubMed ID: 33783868
[TBL] [Abstract][Full Text] [Related]
29. Therapy Modalities for Antibody Mediated Rejection in Renal Transplant Patients.
Yilmaz VT; Suleymanlar G; Koksoy S; Ulger BV; Ozdem S; Akbas H; Akkaya B; Kocak H
J Invest Surg; 2016 Oct; 29(5):282-8. PubMed ID: 27002854
[TBL] [Abstract][Full Text] [Related]
30. Repeated human leukocyte antigens eplets, importance of typing the partner.
Dos Reis Ferreira C; da Silva Fernandes VM; Tafulo SCR; Cerqueira A; Rocha ACB; Nunes ATPM; Ferreira IPCN; Santos MJC; Pinho ATMT; Tavares IC; Guerra MMBB; Norton SMMS
Transpl Immunol; 2024 Jun; 84():102049. PubMed ID: 38729449
[TBL] [Abstract][Full Text] [Related]
31. Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With
Zhu L; Guo Z; Sa R; Guo H; Li J; Chen G
Front Immunol; 2021; 12():661614. PubMed ID: 33936098
[TBL] [Abstract][Full Text] [Related]
32. Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide.
Waiser J; Duerr M; Budde K; Rudolph B; Wu K; Bachmann F; Halleck F; Schönemann C; Lachmann N
Transplantation; 2017 Oct; 101(10):2545-2552. PubMed ID: 28009783
[TBL] [Abstract][Full Text] [Related]
33. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
34. Acute Anti-A/B Antibody-Mediated Rejection After ABO-Incompatible Kidney Transplantation Treated With Bortezomib and Plasmapheresis: A Case Report.
Lee JH; Lee H; Kim K; Lee SW; Song JH; Hwang SD
Transplant Proc; 2022 Mar; 54(2):540-543. PubMed ID: 35067375
[TBL] [Abstract][Full Text] [Related]
35. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
36. Durability of antibody removal following proteasome inhibitor-based therapy.
Everly MJ; Terasaki PI; Trivedi HL
Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
[TBL] [Abstract][Full Text] [Related]
37. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
[TBL] [Abstract][Full Text] [Related]
38. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
39. Treatment of Antibody-Mediated Rejection After Kidney Transplantation: Immunological Effects, Clinical Response, and Histological Findings.
de Sousa MV; Gonçalez AC; de Lima Zollner R; Mazzali M
Ann Transplant; 2020 Nov; 25():e925488. PubMed ID: 33199675
[TBL] [Abstract][Full Text] [Related]
40. Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey.
Burton SA; Amir N; Asbury A; Lange A; Hardinger KL
Clin Transplant; 2015 Feb; 29(2):118-23. PubMed ID: 25430052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]